Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment

Author:

Slowley Alexander1ORCID,Weinmann Sofie2,d'Estrube Tim1,Phiri Kelesitse3,Karl Florian M.2,Gleißner Erika2,Mueller Sabrina4,Junker Sophia5,Göthert Joachim R.6

Affiliation:

1. GSK, Value, Evidence and Outcomes Europe London UK

2. GSK Munich Germany

3. GSK Collegeville Pennsylvania USA

4. IPAM Wismar Germany

5. Ingress‐Health HWM GmbH, a Cytel Company Berlin Germany

6. Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ) University Hospital Essen Germany

Abstract

AbstractObjectivesThere is limited data on the incidence, prevalence, and treatments for myelofibrosis (MF) in Germany. This retrospective study examined claims data from 3.3 million insured individuals, spanning from 2010 to 2021.MethodsFour sensitivity scenarios were explored to identify cases of MF. Point prevalence and cumulative incidence of MF were determined as of December 31, 2021, and within 2021, respectively. A cross‐sectional analysis used the main scenario definition of MF to identify cases and evaluate the period prevalence of patients receiving treatment for symptoms and/or splenomegaly, including first‐line (1L) Janus kinase inhibitor (JAKi), second‐line, or further (2L+) MF‐related treatment therapies during 2021. The prevalence of anemia treatment was also reported.ResultsThe estimated standardized point prevalence of MF on December 31, 2021, was 9.9–12.4 cases per 100 000 persons, and cumulative incidence in 2021 was 1.2–1.8 cases per 100 000 persons. Standardized period prevalence in 2021 for MF patients receiving 1L JAKi and/or 2L+ MF‐related treatment was 4.0 cases per 100 000. Among these patients, 47.1%–53.7% required treatment for anemia, resulting in a period prevalence of 1.9–2.2 cases per 100 000 individuals.ConclusionThe data reveal gaps in MF treatments and the need to improve patient quality of life.

Funder

GlaxoSmithKline

Publisher

Wiley

Reference36 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3